LM ODD for Lung Cancer Patients

by | Mar 6, 2025 | LM

FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Lung Cancer Patients with Leptomeningeal Metastases We are thrilled to announce that the U.S. FDA has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of...

Advancing Treatment for Recurrent Glioblastoma

by | Mar 2, 2025 | GBM

ReSPECT-GBM Clinical Trial: Advancing Treatment for Recurrent Glioblastoma (GBM) Glioblastoma (GBM) is one of the most aggressive and treatment-resistant brain cancers, with limited therapeutic options available for patients with recurrent disease. The ReSPECT-GBM...

#RareDiseaseDay2025

by | Feb 28, 2025 | GBM, LM, PBC, Uncategorized

Shining a Light on Rare Diseases: Raising Awareness Together At Plus Therapeutics, we are committed to advancing research and innovative treatments for rare and challenging diseases. Today, on Rare Disease Day, we stand with patients, caregivers, and advocates...

ReSPECT-LM Phase 1 Single Dose Completed

by | Feb 26, 2025 | LM

BREAKING NEWS: ReSPECT-LM Phase 1 Single Dose Completed – Phase 2 Dose Determined We are thrilled to announce a major milestone in the ReSPECT-LM clinical trial! The Phase 1 single-dose portion of the trial is now complete, and the recommended Phase 2 dose (RP2D) for...

CNSide Diagnostics Leadership Appointments

by | Feb 25, 2025 | LM

Plus Therapeutics Announces Key Leadership Appointments for CNSide Diagnostics, LLC We are excited to announce the appointment of Russell Bradley as President and General Manager of CNSide Diagnostics, LLC, a Plus Therapeutics subsidiary focused on advancing...